These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

85 related articles for article (PubMed ID: 28940411)

  • 1. The impact of perioperative CA19-9 change on the survival and recurrence patterns after adjuvant chemoradiotherapy in resectable extrahepatic cholangiocarcinoma.
    Kim BH; Kim E; Kim K; Jang JY; Kim SW; Oh DY; Chie EK
    J Surg Oncol; 2018 Mar; 117(3):380-388. PubMed ID: 28940411
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Elevated perioperative serum CA 19-9 levels are independent predictors of poor survival in patients with resectable cholangiocarcinoma.
    Kondo N; Murakami Y; Uemura K; Sudo T; Hashimoto Y; Sasaki H; Sueda T
    J Surg Oncol; 2014 Sep; 110(4):422-9. PubMed ID: 24889968
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Prognostic value of carbohydrate antigen 19-9 in patients undergoing resection of biliary tract cancer.
    Yamashita S; Passot G; Aloia TA; Chun YS; Javle M; Lee JE; Vauthey JN; Conrad C
    Br J Surg; 2017 Feb; 104(3):267-277. PubMed ID: 28052308
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Can preoperative and postoperative CA19-9 levels predict survival and early recurrence in patients with resectable hilar cholangiocarcinoma?
    Wang JK; Hu HJ; Shrestha A; Ma WJ; Yang Q; Liu F; Cheng NS; Li FY
    Oncotarget; 2017 Jul; 8(28):45335-45344. PubMed ID: 28484084
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The impact of resection margin status and postoperative CA19-9 levels on survival and patterns of recurrence after postoperative high-dose radiotherapy with 5-FU-based concurrent chemotherapy for resectable pancreatic cancer.
    Kinsella TJ; Seo Y; Willis J; Stellato TA; Siegel CT; Harpp D; Willson JK; Gibbons J; Sanabria JR; Hardacre JM; Schulak JP
    Am J Clin Oncol; 2008 Oct; 31(5):446-53. PubMed ID: 18838880
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Long-Term Outcome of Distal Cholangiocarcinoma after Pancreaticoduodenectomy Followed by Adjuvant Chemoradiotherapy: A 15-Year Experience in a Single Institution.
    Kim BH; Kim K; Chie EK; Kwon J; Jang JY; Kim SW; Oh DY; Bang YJ
    Cancer Res Treat; 2017 Apr; 49(2):473-483. PubMed ID: 27554480
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Postoperative CA19-9 Change Is a Useful Predictor of Intrahepatic Cholangiocarcinoma Survival following Liver Resection.
    Yoo T; Park SJ; Han SS; Kim SH; Lee SD; Kim YK; Kim TH; Woo SM; Lee WJ; Hong EK
    Dis Markers; 2015; 2015():298985. PubMed ID: 26839445
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Role of adjuvant therapy after R0 resection for patients with distal cholangiocarcinoma.
    Kim YS; Hwang IG; Park SE; Go SI; Kang JH; Park I; Oh SY; Ji JH; Song HN; Park SH; Kim ST; Park JO
    Cancer Chemother Pharmacol; 2016 May; 77(5):979-85. PubMed ID: 27017615
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Preoperative serum CA19-9 levels is an independent prognostic factor in patients with resected hilar cholangiocarcinoma.
    Cai WK; Lin JJ; He GH; Wang H; Lu JH; Yang GS
    Int J Clin Exp Pathol; 2014; 7(11):7890-8. PubMed ID: 25550829
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Sustained Elevation of Postoperative Serum Level of Carbohydrate Antigen 19-9 is High-Risk Stigmata for Primary Hepatic Recurrence in Patients with Curatively Resected Pancreatic Adenocarcinoma.
    Motoi F; Murakami Y; Okada KI; Matsumoto I; Uemura K; Satoi S; Sho M; Honda G; Fukumoto T; Yanagimoto H; Kinoshita S; Kurata M; Aoki S; Mizuma M; Yamaue H; Unno M;
    World J Surg; 2019 Feb; 43(2):634-641. PubMed ID: 30298281
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Implications of CA19-9 elevation for survival, staging, and treatment sequencing in intrahepatic cholangiocarcinoma: A national cohort analysis.
    Bergquist JR; Ivanics T; Storlie CB; Groeschl RT; Tee MC; Habermann EB; Smoot RL; Kendrick ML; Farnell MB; Roberts LR; Gores GJ; Nagorney DM; Truty MJ
    J Surg Oncol; 2016 Sep; 114(4):475-82. PubMed ID: 27439662
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prognostic Value of Carbohydrate Antigen 19-9 and the Surgical Margin in Extrahepatic Cholangiocarcinoma.
    Yamamoto R; Sugiura T; Ashida R; Ohgi K; Yamada M; Otsuka S; Uesaka K
    Ann Gastroenterol Surg; 2022 Mar; 6(2):307-315. PubMed ID: 35261957
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comparison of the prognostic impact of pre- and post-operative CA19-9, SPan-1, and DUPAN-II levels in patients with pancreatic carcinoma.
    Kondo N; Murakami Y; Uemura K; Nakagawa N; Takahashi S; Ohge H; Sueda T
    Pancreatology; 2017; 17(1):95-102. PubMed ID: 27746094
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prognostic relevance of preoperative bilirubin-adjusted serum carbohydrate antigen 19-9 in a multicenter subset analysis of 179 patients with distal cholangiocarcinoma.
    Bolm L; Petrova E; Weitz J; Rückert F; Wittel UA; Makowiec F; Lapshyn H; Bronsert P; Rau BM; Khatkov IE; Bausch D; Keck T; Wellner UF; Distler M
    HPB (Oxford); 2019 Nov; 21(11):1513-1519. PubMed ID: 30956162
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Value of postoperative adjuvant chemotherapy in locally advanced rectal cancer patients with ypT1-4N0 after neo-adjuvant chemoradiotherapy].
    You KY; Peng HH; Gao YH; Chen L; Zhou GQ; Chang H; Du XJ; Xiao L; Zeng ZF; Wen BX; Liu MZ
    Zhonghua Zhong Liu Za Zhi; 2013 Sep; 35(9):708-13. PubMed ID: 24332061
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Postoperative serum CEA and CA125 levels are supplementary to perioperative CA19-9 levels in predicting operative outcomes of pancreatic ductal adenocarcinoma.
    Xu HX; Liu L; Xiang JF; Wang WQ; Qi ZH; Wu CT; Liu C; Long J; Xu J; Ni QX; Yu XJ
    Surgery; 2017 Feb; 161(2):373-384. PubMed ID: 27838102
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Staging, prognostic factors and adjuvant therapy of intrahepatic cholangiocarcinoma after curative resection.
    Li T; Qin LX; Zhou J; Sun HC; Qiu SJ; Ye QH; Wang L; Tang ZY; Fan J
    Liver Int; 2014 Jul; 34(6):953-60. PubMed ID: 24134199
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Role of adjuvant chemoradiotherapy for resected extrahepatic biliary tract cancer.
    Kim TH; Han SS; Park SJ; Lee WJ; Woo SM; Moon SH; Yoo T; Kim SS; Kim SH; Hong EK; Kim DY; Park JW
    Int J Radiat Oncol Biol Phys; 2011 Dec; 81(5):e853-9. PubMed ID: 21497455
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Evaluation of serum D-dimer, fibrinogen, and CA19-9 for postoperative monitoring and survival prediction in resectable pancreatic carcinoma.
    Cao J; Fu Z; Gao L; Wang X; Cheng S; Wang X; Ren H
    World J Surg Oncol; 2017 Feb; 15(1):48. PubMed ID: 28219450
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Post-adjuvant chemotherapy CA19-9 levels predict prognosis in patients with pancreatic ductal adenocarcinoma: A retrospective cohort study.
    Imaoka H; Shimizu Y; Senda Y; Natsume S; Mizuno N; Hara K; Hijioka S; Hieda N; Tajika M; Tanaka T; Ishihara M; Niwa Y; Yamao K
    Pancreatology; 2016; 16(4):658-64. PubMed ID: 27178104
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.